These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 19546143)

  • 1. Reimbursement for drugs -- a register study comparing economic outcome for five healthcare centres in areas with different socioeconomic conditions.
    Semark B; Fredlund K; Astrand B; Brudin L
    Scand J Public Health; 2009 Aug; 37(6):647-53. PubMed ID: 19546143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Social status affects drug costs and health care costs. A registry study shows that Care Choice should take socioeconomic factors into account].
    Engström S; Magnusson H; Enthoven P; Walter L; Thorell K; Halling A; Borgquist L
    Lakartidningen; 2009 Nov 25-Dec 1; 106(48):3248, 3250, 3252-3. PubMed ID: 20101836
    [No Abstract]   [Full Text] [Related]  

  • 3. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional variations and determinants of direct psychiatric costs in Sweden.
    Tiainen A; Edman G; Flyckt L; Tomson G; Rehnberg C
    Scand J Public Health; 2008 Jul; 36(5):483-92. PubMed ID: 18635731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary health care reimbursement based on socio-economics or disease burden. Registry study from Ostergotland shows different results depending on analysis level].
    Borgquist L; Andersson D; Engström S; Magnusson H
    Lakartidningen; 2010 Sep 15-21; 107(37):2158-63. PubMed ID: 21043155
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors influencing the prescription of drugs of different price levels.
    Semark B; Engström S; Brudin L; Tågerud S; Fredlund K; Borgquist L; Petersson G
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):286-93. PubMed ID: 23349104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Education and drug use in Sweden--a nationwide register-based study.
    Weitoft GR; Rosén M; Ericsson O; Ljung R
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):1020-8. PubMed ID: 18720428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey.
    Hjollund NH; Larsen FB; Andersen JH
    Scand J Public Health; 2007; 35(5):497-502. PubMed ID: 17852980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis.
    Wiréhn AB; Andersson A; Ostgren CJ; Carstensen J
    Diabet Med; 2008 Jun; 25(6):732-7. PubMed ID: 18435778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The costs and benefits of regulations for reimbursement of new drugs.
    Lundkvist J; Jönsson B; Rehnberg C
    Health Policy; 2006 Dec; 79(2-3):337-44. PubMed ID: 16549221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.
    Westerlund T; Marklund B
    J Clin Pharm Ther; 2009 Jun; 34(3):319-27. PubMed ID: 19646078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic catastrophes: exploring the concentration and sustained nature of ambulatory prescription drug expenditures in the population of British Columbia, Canada.
    Hanley GE; Morgan S
    Soc Sci Med; 2009 Mar; 68(5):919-24. PubMed ID: 19135288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition cost of dispensed drugs in individuals with multiple medications--a register-based study in Sweden.
    Hovstadius B; Åstrand B; Persson U; Petersson G
    Health Policy; 2011 Jul; 101(2):153-61. PubMed ID: 21514685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
    Keiding H; Faergeman O
    Ugeskr Laeger; 2008 Feb; 170(8):651-4. PubMed ID: 18364159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people.
    Johnell K; Weitoft GR; Fastbom J
    Ann Pharmacother; 2009 Jul; 43(7):1233-8. PubMed ID: 19584395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Explaining primary healthcare pharmacy expenditure using classification of medications for chronic conditions.
    Vivas D; Guadalajara N; Barrachina I; Trillo JL; Usó R; de-la-Poza E
    Health Policy; 2011 Nov; 103(1):9-15. PubMed ID: 21956046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.